RYSTIGGO

This brand name is authorized in Austria, Estonia, France, Croatia, Lithuania, Romania, United States

Active ingredients

The drug RYSTIGGO contains one active pharmaceutical ingredient (API):

1 Rozanolixizumab UNII P7186074QC - ROZANOLIXIZUMAB

Rozanolixizumab is a humanised IgG4 monoclonal antibody that decreases serum IgG concentration by inhibiting the binding of IgG to FcRn, a receptor that under physiological conditions protects IgG from intracellular degradation and recycles IgG back to the cell surface. By the same mechanism, rozanolixizumab decreases the concentration of pathogenic IgG autoantibodies associated with generalised myasthenia gravis (gMG). Read about Rozanolixizumab

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
RYSTIGGO Solution for injection	FDA, National Drug Code (US)	MPI, US: SPL/PLR
RYSTIGGO Solution for injection	European Medicines Agency (EU)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
L04AG16		L Antineoplastic and immunomodulating agents → L04 Immunosuppressants → L04A Immunosuppressants → L04AG Monoclonal antibodies
Discover more medicines within L04AG16

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: EE	Ravimiamet	Identifier(s): 3062966
Country: FR	Base de données publique des médicaments	Identifier(s): 68822785
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1098627
Country: RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	Identifier(s): W70053001
Country: US	FDA, National Drug Code	Identifier(s): 50474-980